BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/25/2025 12:09:41 PM | Browse: 2 | Download: 0
 |
Received |
|
2025-03-10 08:54 |
|
Peer-Review Started |
|
2025-03-11 00:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-09 12:49 |
|
Revised |
|
2025-04-19 15:04 |
|
Second Decision |
|
2025-06-13 02:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-13 06:55 |
|
Articles in Press |
|
2025-06-13 06:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-16 01:09 |
|
Publish the Manuscript Online |
|
2025-07-25 12:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Ajib Zaim Alamsyah, Ni Luh Putu Yunia Dewi, Ni Nyoman Gita Kharisma Dewi, I Ketut Mariadi and Dwijo Anargha Sindhughosa |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dwijo Anargha Sindhughosa, MD, Researcher, Divison of Gastroenterology and Hepatology, Department of Internal Medicine, Udayana University, Faculty of Medicine, Jl. Diponegoro, Denpasar, Bali, Denpasar 80113, Bali, Indonesia. dwijo_anargha@unud.ac.id |
| Key Words |
Hepatocellular carcinoma; Immune checkpoint inhibitors; Targeted therapy; Gut microbiome; Intervention-focused modulation |
| Core Tip |
Combination of immune checkpoint inhibitor (ICI) therapy has improved efficacy and survival in patients with unresectable hepatocellular carcinoma (HCC). However, a substantial proportion still fail to respond due to resistance driven by the tumor microenvironment. Emerging strategies targeting gut microbiota offer promising avenues to overcome this barrier. Certain microbial taxa have been associated with enhanced T-cell infiltration and improved ICI responses. Additionally, microbial metabolites like butyrate and desaminotyrosine exert immunomodulatory effects that may restore sensitivity to ICIs. Dual-target approaches combining ICIs and microbiota modulation hold potential to improve progression-free and overall survival in HCC. |
| Publish Date |
2025-07-25 12:09 |
| Citation |
<p>Pamungkas KMN, Lesmana Dewi PIS, Alamsyah AZ, Dewi NLPY, Dewi NNGK, Mariadi IK, Sindhughosa DA. Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management. <i>World J Hepatol</i> 2025; 17(7): 106810</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i7/106810.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i7.106810 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
